Table 5.
Previous reports on EGFR mutation test from circulating free DNA
| Year | Authors | Subjects | DNA concentration | Mutation test | Detection rate |
|---|---|---|---|---|---|
| 2006 |
Kimura H, et al. [16] |
Asian |
70 ng/mL (range, 0–1720 ng/mL) |
SARMS |
48.1% (13/27) |
| Female : 37% | |||||
| Nonsmoker : N/A | |||||
| ADC : 85% | |||||
| ORR : 33% | |||||
| 2008 |
Maheswaran S, et al. [24] |
Western |
N/A |
SARMS |
39% (7/18) |
| EGFR mutant patients | |||||
| 2009 |
He C, et al. [29] |
Asian |
N/A |
Mutant-enriched PCR |
49.3% (66/134) |
| Female : 37% | |||||
| Nonsmoker : 53% | |||||
| ADC : 75% | |||||
| 2009 |
Bai H, et al. [28] |
Asian |
N/A |
dHPLC |
34.3% (79/230) |
| Female : 46% | |||||
| Nonsmoker : 55% | |||||
| ADC : 74% | |||||
| ORR : 36% (37/102) | |||||
| 2009 |
Mack PC, et al. [26] |
Western/Asian : 96/4% |
2.3 ng/μL (range, 1–9 ng/μL ) |
SARMS |
20% (10/49) |
| Female : 56% | |||||
| Nonsmoker : 53% | |||||
| ADC : 67% | |||||
| 2009 |
Kuang Y, et al. [25] |
Western |
52.3 ng/μL (range, 10–163 ng/μL ) |
SARMS and WAVE/Surveyor |
54% (29/54) |
| Female : 81.5% | |||||
| Whole genome amplification | |||||
| Nonsmoker : N/A | |||||
| ADC : N/A | |||||
| ORR : 56% | |||||
| 2010 |
Brevet M, et al. [31] |
Western |
N/A |
Mass spectrometry genotyping assay (Sequenom) and mutant-enriched PCR Whole genome amplification |
23.2% (10/31) |
| Female : 52% | |||||
| Nonsmoker : 45% | |||||
| ADC : 97% | |||||
| 2010 |
Jian G, et al. [27] |
Asian |
N/A |
Taqman PCR |
23.2% (13/56) |
| Female : 46% | |||||
| Nonsmoker : 58% | |||||
| ADC : 78% | |||||
| ORR : 30% | |||||
| 2011 |
Jiang B, et al. [30] |
Asian |
Minimum 4 ng/μL (range, 11–66 ng/μL ) |
Mutant-enriched PCR |
31% (18/58) |
| Female : 31% | |||||
| Nonsmoker : 38% | |||||
| ADC : 72% | |||||
| 2011 |
Taniguchi K, et al. [32] |
Asian |
N/A |
BEAMing |
72.7% (32/44) |
| EGFR mutant patients | |||||
| This study |
Kim HR, et al. |
Asian |
8.6 ng/μL |
PNA-based PCR clamping |
16.7% (10/60) |
| Female : 65% | |||||
| Nonsmoker : 2% | |||||
| ADC : 88% | |||||
| ORR : 100% |
Abbreviations: ADC adenocarcinoma, SARMS scorpion-amplified refractory mutation system, PCR polymerase chain reaction, dHPLC denaturing high-performance liquid chromatography, BEAMing beads, emulsion, amplification, and magnetics, PNA peptide nucleic acid.